{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:14:53Z","timestamp":1791724493996,"version":"4.3.4"},"reference-count":44,"publisher":"Massachusetts Medical Society","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["NEJM Evidence"],"published-print":{"date-parts":[[2025,3,25]]},"DOI":"10.1056\/evidoa2400229","type":"journal-article","created":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T09:31:27Z","timestamp":1742895087000},"source":"Crossref","is-referenced-by-count":50,"title":["Associations between Class I, II, or III Obesity and Health Outcomes"],"prefix":"10.1056","volume":"4","author":[{"given":"Zhiqi","family":"Yao","sequence":"first","affiliation":[{"name":"Johns Hopkins Ciccarone Center for Prevention of Cardiovascular Disease, Baltimore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverly G.","family":"Tchang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology, Weill Cornell Medical College, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Albert","sequence":"additional","affiliation":[{"name":"University of Oklahoma Health Sciences Center, Oklahoma City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger S.","family":"Blumenthal","sequence":"additional","affiliation":[{"name":"Johns Hopkins Ciccarone Center for Prevention of Cardiovascular Disease, Baltimore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khurram","family":"Nasir","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Prevention and Wellness, Department of Cardiology, Houston Methodist DeBakey Heart and Vascular Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Blaha","sequence":"additional","affiliation":[{"name":"Johns Hopkins Ciccarone Center for Prevention of Cardiovascular Disease, Baltimore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"150","reference":[{"key":"e_1_3_4_2_2","volume-title":"Prevalence of overweight, obesity, and severe obesity among adults aged 20 and over: United States, 1960\u20131962 through 2017\u20132018","unstructured":"Fryar CD, Carroll MD, Afful J. Prevalence of overweight, obesity, and severe obesity among adults aged 20 and over: United States, 1960\u20131962 through 2017\u20132018. Hyattsville, MD: NCHS, Health E-Stats, 2020."},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa1909301"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2009.07.008"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62076-0"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-9-88"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2017.03.107"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/epirev\/mxm008"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.117333"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.05.057"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.2147\/IJNRD.S39739"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.003921"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/jce.13458"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-020-00582-9"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2005.06.007"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2021.05.008"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60318-4"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30288-2"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30175-1"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2020.06.058"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2023.7733"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/jamia\/ocad260"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.5888\/pcd18.210094"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsr1809937"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2016.183"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.patter.2022.100570"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/NT.0000000000000092"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a121617"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12940-019-0492-4"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0255583"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annepidem.2014.11.010"},{"key":"e_1_3_4_32_2","unstructured":"U.S. Food and Drug Administration. FDA approves first treatment for patients with liver scarring due to fatty liver disease. Silver Spring MD: U.S. Food and Drug Administration. March 14 2024 (https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease)."},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00803-X"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2404881"},{"key":"e_1_3_4_35_2","unstructured":"Eli Lilly and Company. Tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and Obesity. April 17 2024 (https:\/\/investor.lilly.com\/news-releases\/news-release-details\/tirzepatide-reduced-sleep-apnea-severity-nearly-two-thirds)."},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307563"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2313917"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2023.07.006"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2306963"},{"key":"e_1_3_4_40_2","unstructured":"Freeborn J. Heart failure: weight loss drug Zepbound may improve physical function. Brighton: Medical News Today August 6 2024 (https:\/\/www.medicalnewstoday.com\/articles\/weight-loss-drug-zepbound-may-reduce-death-risk-heart-failure)."},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001184"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kws448"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000004"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.13044"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2019.11.019"}],"container-title":["NEJM Evidence"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T18:27:01Z","timestamp":1751480821000},"score":1,"resource":{"primary":{"URL":"https:\/\/evidence.nejm.org\/doi\/10.1056\/EVIDoa2400229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,25]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,3,25]]}},"alternative-id":["10.1056\/EVIDoa2400229"],"URL":"https:\/\/doi.org\/10.1056\/evidoa2400229","relation":{},"ISSN":["2766-5526"],"issn-type":[{"value":"2766-5526","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,25]]}}}